Health News

NEW YORK--(BUSINESS WIRE)--Judi Health™, the enterprise health technology company and benefits administrator, today announced that Capital Rx, the transparent, full-service pharmacy benefit manager (PBM), is now Judi Rx™. Additionally, the company has launched Judi Care™ for medical benefit administration, and Judi Cloud™ to facilitate licensing of the Judi® platform to health plans and third-party administrators (TPAs). This strategic evolution follows the company’s $400 million financing roun...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs.The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.About Ionis Pharmaceuticals, Inc.For three decades, Ionis has invented me...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026...

BREMEN, Germany--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.DISQVER® enables metagenomic next-generation sequencing (mNGS) analysis of microbes directly from blood samples, further expanding Bruker's NGS-based infection detection capabilities. Without any need for prior cultivation, DISQVER analyzes whole genome sequencing (WGS) data and applies advanced, proprietary bioinformatics to search...

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referenc...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from its open-label Phase 2 clinical trial (Study ‘207’) evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-moderate pattern hair loss. VDPHL01 has the potential to become the first FDA-approved oral...

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Pediatrix Medical Group, Inc. (NYSE: MD) (“Pediatrix” or “the Company”), a leading provider of physician services, today provided an update on its second quarter 2026 business trends. In response to recent reports from other healthcare market participants regarding shifting utilization and reimbursement trends, the Company confirms that its payor mix for the second quarter remained stable and unchanged relative to recent historical trends and the Company’...

RAHWAY, N.J.--(BUSINESS WIRE)--KEYTRUDA as Monotherapy Significantly Improved PFS in Certain Patients With Advanced or Recurrent Endometrial Cancer Compared to Chemotherapy...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on September 8, 2026 to shareholders of record at the close of business on August 25, 2026. The ex-dividend date is August 25, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare inn...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2026. “Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world’s toughest health challenges,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With raised guidance and quarterly...